Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity

Oncogene volume 22, pages 3288–3296 (2003)Cite this article

Abstract

Most tumour suppressor genes (TSGs) have been found through linkage studies in cancer predisposed families where the mutations have a high penetrance, for example, the breast cancer genes BRCA1 and BRCA2. Loss of heterozygosity (LOH) analyses of sporadic breast tumours indicate that there are many other putative TSGs yet to be identified. One such locus is proximal to BRCA1 on human chromosome 17q21. In an attempt to isolate this putative TSG, we have assessed a portion of the orthologous region on mouse chromosome 11 for its tumorigenic potential using segmental haploidy in combination with a p53 mutation. Two populations of animals were studied, with the deleted region being either on the same (cis) or on the homologous chromosome (trans) to a targeted mutant p53 allele. The deficiency elevated the tumour susceptibility of p53 heterozygous mice and modified the tumour spectrum, but only when the deficiency was in trans with the p53 mutation. Even though the genotype of these mice is identical, allelic phasing affects both the tumour spectrum and progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Anglian Breast Cancer Study Group. (2000). Br. J. Cancer, 83, 1301–1308.

  • Balmain A . (2002a). Cell, 108, 145–152.

  • Balmain A . (2002b). Nature, 417, 235–237.

  • Bradley A, Zheng B and Liu P . (1998). Int. J. Dev. Biol., 42, 943–950.

  • Church GM and Gilbert W . (1984). Proc. Natl. Acad. Sci. USA, 81, 1991–1995.

  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A . (1992). Nature, 356, 215–221.

  • Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery Jr CA, Park SH, Thompson T, Ford RJ and Bradley A . (1995). Mol. Carcinogen., 14, 16–22.

  • Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Söderkvist P, Terry L, Jhanwar S, Berchuck A, Igleheart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A and Wiseman R . (1994). Science, 266, 120–122.

  • Harvey M, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A and Donehower LA . (1993). Nat. Genet., 5, 225–229.

  • Liu P, Zhang H, McLellan A, Vogel H and Bradley A . (1998). Genetics, 150, 1155–1168.

  • Luo G, Santoro IM, McDaniel LD, Nishijima I, Mills M, Youssoufian H, Vogel H, Schultz RA and Bradley A . (2000). Nat. Genet., 26, 424–429.

  • MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V and Gusella J . (1993). JAMA, 270, 2316–2320.

  • Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C and Frank TS . (1995). Nat. Genet., 9, 439–443.

  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S Wray C, Bogden R Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH . (1994). Science, 266, 66–71.

  • Osborne RJ and Hamshere MG . (2000). Cancer Res., 60, 3706–3712.

  • Ponder BA . (2001). Nature, 411, 336–341.

  • Ramirez-Solis R, Liu P and Bradley A . (1995). Nature, 378, 720–724.

  • Staff S, Nupponen NN, Borg A, Isola JJ and Tanner MM . (2000). Genes Chromosomes Cancer, 28, 432–442.

  • Su H, Wang X and Bradley A . (2000). Nat. Genet., 24, 92–95.

  • Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF and Taketo MM . (1998). Cell, 92, 645–656.

  • Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE, Mitchell JT McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick MH, Weber B and Kamb A . (1996). Nat. Genet., 12, 333–337.

  • Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D and Donehower LA . (1998). EMBO J., 17, 4657–4667.

  • Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG and Jenkins NA . (1990). Cell, 62, 187–192.

  • Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ and Parada LF . (1999). Science, 286, 2176–2179.

  • Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G . (1995). Nature, 378, 789–792.

  • Zheng B, Mills AA and Bradley A . (1999a). Nucleic Acids Res., 27, 2354–2360.

  • Zheng B, Sage M, Cai WW, Thompson DM, Tavsanli BC, Cheah YC and Bradley A . (1999b). Nat. Genet., 22, 375–378.

Download references

Acknowledgements

We thank Janis Wesley and Andrew Salinger for their help with the animal husbandry. This work was supported by grants from the National Cancer Institute and the Howard Hughes Medical Institute.

Author information

Author notes

  1. Hannes Vogel

    Present address: Department of Pathology (Neuropathology), Stanford University Medical Center R241, 300 Pasteur Drive, Stanford, CA, 94305, USA

Authors and Affiliations

  1. The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA, Cambs, UK

    Patrick J Biggs, Lucy A Martin & Allan Bradley

  2. Department of Pathology, Baylor College of Medicine, Houston, 77030, TX, USA

    Hannes Vogel

  3. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, 77030, TX, USA

    Marijke Sage

  4. Division of Molecular Virology, Baylor College of Medicine, Houston, 77030, TX, USA

    Larry A Donehower

Authors
  1. Patrick J Biggs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannes Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marijke Sage
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lucy A Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Larry A Donehower
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Allan Bradley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allan Bradley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biggs, P., Vogel, H., Sage, M. et al. Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity. Oncogene 22, 3288–3296 (2003). https://doi.org/10.1038/sj.onc.1206384

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206384

Keywords

This article is cited by

Search

Advanced search

Quick links